Litcius/Paper detail

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

Geert D’Haens, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean–Frédéric Colombel, Silvio Danese, Marla C. Dubinsky, Brian G. Feagan, Tadakazu Hisamatsu, Allen Lim, James O. Lindsay, Edward V. Loftus, Julián Panés, Laurent Peyrin‐Biroulet, Zhihua Ran, David T. Rubin, William J. Sandborn, Stefan Schreiber, Ezequiel Neimark, Alexandra Song, Kristina Kligys, Yinuo Pang, Valerie Pivorunas, Sofie Berg, W. Rachel Duan, Bidan Huang, Jasmina Kalabic, Xiaomei Liao, Anne Robinson, Kori Wallace, Marc Ferrante

2022The Lancet390 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePlaceboCrohn's diseaseInternal medicinePopulationClinical trialRandomized controlled trialDiseasePhysical therapyAlternative medicineEnvironmental healthPathologyInflammatory Bowel DiseasePsoriasis: Treatment and PathogenesisRheumatoid Arthritis Research and Therapies
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials | Litcius